Worth reading
52Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
28
¥100 million (expected expense reductions)Wording
Conditional
How definitive the wording is.Items stated in the management plan
Net SalesNot disclosed → 606 (target for the fiscal year ending March 2031)
Operating profitNot disclosed → 46 (target for the fiscal year ending March 2031)
Only the target level is shown because the current level for comparison was not provided.What happened to the previous planConsolidated operating profit of ¥15.0 billion (target under Medium-Term Management Plan 2025) → Consolidated operating loss of ¥4,688 million (actual result for the fiscal year ended March 2026)+131.5%Calculated from the two disclosed figures
Key initiatives
01Discontinuation of the in-house clinical development project for gene therapy
02Withdrawal from GMP cell-processing contract services and prioritization of target modalities
03Clarification of management responsibility and streamlining of the management structure
04Workforce optimization
05In the reagents and instruments business, the company will expand earnings while limiting increases in allocated resources, in response to declining profitability of research catalog products amid the downturn in the global life sciences research market.
06In the CDMO business, the company will pursue thorough expense reductions, including through these structural reforms.
07In the gene medicine business, the company will continue to develop and manufacture for business-to-business customers, and focus on expanding sales, of biopharmaceutical manufacturing auxiliaries and media products, including RetroNectin® and enzymes for mRNA vaccine production, which are products for the regenerative medicine, cell therapy, and gene therapy fields that are expected to achieve further growth.
08To achieve medium- to long-term growth, the company will expand its business beyond its traditional healthcare and medical fields into areas including the environment, industrial and energy applications, marine applications, and food and plants, using biotechnology, and will build a portfolio of technologies, products and services.
Plan assumptionsThe global life sciences research market will remain sluggish, Further growth is expected in the regenerative medicine, cell therapy, and gene therapy fields
Non-financial targetsIndicator name Number of Directors / Target value 3 (reduced from 9) / Timing Expected to be formally decided by resolution at the 24th Annual General Meeting of Shareholders, Indicator name Number of voluntary retirements solicited / Target value Approximately 120 people / Timing Application period: 15 June 2026 to 17 July 2026
Risks identified by the company
Economic conditions, particularly consumer trends
Changes in Exchange Rates
Changes in laws and administrative systems
Pressure from competitors’ pricing and product strategies
Declining sales capability for existing and new products
Production interruptions
Infringement of intellectual property rights
Rapid technological innovation
An unfavorable judgment in significant litigation
Other factors affecting business performance
Reason for revision or withdrawal
The full-year results for the fiscal year ended March 2026 resulted in a consolidated operating loss of ¥4,688 million, significantly missing the consolidated operating profit target of ¥15.0 billion under Medium-Term Management Plan 2025. This reflected the continuing global downturn in the life sciences research market, substantial cuts in research grants in the United States, intensifying competition with competitors in China, a downward trend in development projects from major pharmaceutical companies in Japan's regenerative medicine, cell therapy, and gene therapy fields, and a decrease in CDMO contract projects due to changes in customers' development policies, among other factors.
| Item | Details |
|---|---|
| Plan name | Medium-Term Management Plan 2025 |
| Plan period | Three-year period ending in fiscal 2025 |
| Sales Target | Not disclosed → 606 (target for the fiscal year ending March 2031) |
| Operating profit target | Not disclosed → 46 (target for the fiscal year ending March 2031) |
| Non-financial targets | Indicator name Number of Directors / Target value 3 (reduced from 9) / Timing Expected to be formally decided by resolution at the 24th Annual General Meeting of Shareholders, Indicator name Number of voluntary retirements solicited / Target value Approximately 120 people / Timing Application period: 15 June 2026 to 17 July 2026 |
| Plan assumptions | The global life sciences research market will remain sluggish, Further growth is expected in the regenerative medicine, cell therapy, and gene therapy fields |
| Key initiatives | Discontinuation of the in-house clinical development project for gene therapy, Withdrawal from GMP cell-processing contract services and prioritization of target modalities, Clarification of management responsibility and streamlining of the management structure, Workforce optimization, In the reagents and instruments business, the company will expand earnings while limiting increases in allocated resources, in response to declining profitability of research catalog products amid the downturn in the global life sciences research market., In the CDMO business, the company will pursue thorough expense reductions, including through these structural reforms., In the gene medicine business, the company will continue to develop and manufacture for business-to-business customers, and focus on expanding sales, of biopharmaceutical manufacturing auxiliaries and media products, including RetroNectin® and enzymes for mRNA vaccine production, which are products for the regenerative medicine, cell therapy, and gene therapy fields that are expected to achieve further growth., To achieve medium- to long-term growth, the company will expand its business beyond its traditional healthcare and medical fields into areas including the environment, industrial and energy applications, marine applications, and food and plants, using biotechnology, and will build a portfolio of technologies, products and services. |
| Results under the previous plan | Consolidated operating profit of ¥15.0 billion (target under Medium-Term Management Plan 2025) → Consolidated operating loss of ¥4,688 million (actual result for the fiscal year ended March 2026) |
| Reason for revision or withdrawal | The full-year results for the fiscal year ended March 2026 resulted in a consolidated operating loss of ¥4,688 million, significantly missing the consolidated operating profit target of ¥15.0 billion under Medium-Term Management Plan 2025. This reflected the continuing global downturn in the life sciences research market, substantial cuts in research grants in the United States, intensifying competition with competitors in China, a downward trend in development projects from major pharmaceutical companies in Japan's regenerative medicine, cell therapy, and gene therapy fields, and a decrease in CDMO contract projects due to changes in customers' development policies, among other factors. |
| Risks identified | Economic conditions, particularly consumer trends, Changes in Exchange Rates, Changes in laws and administrative systems, Pressure from competitors’ pricing and product strategies, Declining sales capability for existing and new products, Production interruptions, Infringement of intellectual property rights, Rapid technological innovation, An unfavorable judgment in significant litigation, Other factors affecting business performance |
| Date of board resolution | 13 May 2026 |
| Publication date | 13 May 2026 |
Items this document does not state (13)
Progress against the planOperating profit margin targetNet income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planInvestment amount by sectorSegment targetSize of the Target Market
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The reforms are intended to accelerate the selection and concentration of businesses, withdraw from unprofitable operations, and optimize staffing in order to restore profitability at an early stage. The background includes the loss of ¥4,688 million in operating income for the fiscal year ended March 2026, significantly missing the targets of Medium-Term Management Plan 2025, as a result of the prolonged downturn in the global life sciences research market, cuts in U.S. research grants, intensifying competition in China, declining development projects from major Japanese pharmaceutical companies, and a decrease in CDMO contract projects due to changes in customers' development policies. In anticipation of becoming a wholly owned subsidiary of Takara Holdings, the company also aims to transition to a structure that generates sustainable earnings commensurate with its asset base, while taking synergies into account.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.